123 related articles for article (PubMed ID: 324955)
21. [Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles].
Sismondi P; Zola P; Galletto L; De Giovanni D; Giardina G
Minerva Ginecol; 1979; 31(7-8):563-8. PubMed ID: 481814
[No Abstract] [Full Text] [Related]
22. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy in breast cancer.
Bonadonna G; Rossi A; Tancini G; Valagussa P
Lancet; 1983 May; 1(8334):1157. PubMed ID: 6133169
[No Abstract] [Full Text] [Related]
24. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
26. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.
Mouridsen HT; Palshof T; Brahm M; Rahbek I
Cancer Treat Rep; 1977; 61(1):47-50. PubMed ID: 324620
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemotherapy in the primary management of breast cancer.
Fisher B
Med Clin North Am; 1977 Sep; 61(5):953-65. PubMed ID: 330977
[No Abstract] [Full Text] [Related]
29. [Adjuvant chemotherapy in breast cancer: status in 1984].
Jungi WF
Wien Klin Wochenschr; 1984 Jun; 96(13):486-92. PubMed ID: 6382805
[TBL] [Abstract][Full Text] [Related]
30. [Results of, and indications for adjuvant chemotherapy in breast cancer].
Brunner KW; Goldhirsch A; Joss R; Sonntag RW; Tschopp L
Schweiz Med Wochenschr; 1981 Jun; 111(23):838-45. PubMed ID: 7268339
[TBL] [Abstract][Full Text] [Related]
31. Dose-response effect of adjuvant chemotherapy in breast cancer.
Bonadonna G; Valagussa P
N Engl J Med; 1981 Jan; 304(1):10-5. PubMed ID: 7432433
[TBL] [Abstract][Full Text] [Related]
32. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
[TBL] [Abstract][Full Text] [Related]
33. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO
Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant chemotherapy in breast cancer].
Senn HJ
Dtsch Med Wochenschr; 1981 Nov; 106(48):1626-30. PubMed ID: 7030686
[No Abstract] [Full Text] [Related]
35. Therapy of primary breast cancer.
Holland JF
Isr J Med Sci; 1977 Aug; 13(8):829-36. PubMed ID: 893066
[No Abstract] [Full Text] [Related]
36. Combination chemotherapy as an adjuvant treatment in operable breast cancer.
Bonadonna G; Brusamolino E; Valagussa P; Rossi A; Brugnatelli L; Brambilla C; De Lena M; Tancini G; Bajetta E; Musumeci R; Veronesi U
N Engl J Med; 1976 Feb; 294(8):405-10. PubMed ID: 1246307
[TBL] [Abstract][Full Text] [Related]
37. Surgical adjuvant trials in the United States.
Rozencweig M; Von Hoff DD; Allegra JC; Muggia FM
Eur J Cancer (1965); 1980; Suppl 1():173-7. PubMed ID: 7032929
[No Abstract] [Full Text] [Related]
38. Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.
Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
Eur J Cancer (1965); 1980; Suppl 1():189-95. PubMed ID: 7032932
[No Abstract] [Full Text] [Related]
39. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
40. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
